Phase-II data suggests Sinovac’s vaccine is at least 98.9% effective in producing antibodies among people aged 3 to 17
China's Sinovac COVID-19 vaccine has been approved for emergency use among population aged between 3 and 17 years old, after phase-II clinic trial data suggests it is at least 98.9…